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Abstract
Background: Tuberculin is still the only available skin test reagent for the diagnosis of mycobacterial infection. The product
has a remarkable sensitivity, but poor specificity. Previous studies, including two human phase I clinical trials, have indicated
that rdESAT-6 has a potential as an improved skin test reagent. Animal studies have shown that the sensitivity may be
increased by inclusion of the genetically related CFP-10 antigen in the preparation without loosing specificity.
Methodology: In this study a Lactococcus fermented, recombinant skin test reagent consisting of a 1:1 wt/wt of rdESAT-6
and CFP-10 was manufactured according to GMP standards and tested for the first time in 42 healthy adult volunteers. The
two doses of 0.01 mg or 0.1 mg were injected intradermally by the Mantoux technique with 6 or 12 weeks interval. No
serious adverse events and only mild adverse reactions were reported. The reagent elicited a positive skin test reaction after
the first injection in one participant, who most likely was latently infected with M. tuberculosis as indicated by an appreciable
IFN c response just below the QuantiferonH cut-off level at the screening visit. None of the remaining participants in the
four groups had any skin test reactions and sensitisation by the reagent could therefore be excluded.
Conclusion: The investigational skin test reagent rdESAT-6 and CFP-10 appeared safe and non-sensitising in this first-in-man
clinical trial in human volunteers and can now be tested in larger clinical trials involving individuals with latent M.
tuberculosis infection or active TB disease.
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Introduction
The potential of in vitro based methods to detect immune
reactivity towards tuberculin antigen has been widely accepted in
recent years. Two commercially available assays are based on
immune recognition of the Mycobacterium tuberculosis specific
antigens ESAT-6, CFP-10 and in one of the assays also TB-7.7.
Immune T lymphocytes release interferon-cIFNc after presenta-
tion to the M. tuberculosis antigens and subsequent ELISA or
EliSpot assays quantify the cytokine. An accepted acronym
for such tests is IGRA: Interferon-Gamma-Release-Assays [1,2].
IGRAs have several advantages compared to the conventional
Tuberculin skin test (TST) especially increased specificity. The
antigens included in the IGRAs have been selected based on their
absence in most non-tuberculous mycobacteria and in the vaccine
strain M. bovis BCG altogether limiting ‘‘false positive’’ reactions
[3,4]. However, in many parts of the world laboratory facilities
required to perform an IGRA are not available. Skin testing by the
Mantoux technique with standardised amounts of tuberculin e.g.
Purified Protein derivative (PPD) is indeed a ‘‘low-tech’’
procedure, which is easily performed by trained health care
personnel any time during the day, any day of the week,
independently of the availability of laboratory personnel or
equipment [5].
Tuberculins like PPD are composed of a crude mixture of heat-
denatured proteins derived from cultures of M. tuberculosis. The
purification process ensures the removal of lipids and cell walls but
the exact quantity of the individual antigens is not known and
dosing is based on a biological assay measuring cellular infiltration
(i.e. induration) in the skin of immune guinea pigs as read-out. It is
therefore not surprising that other mycobacteriel species (like the
BCG vaccine strain) possessing cross-reactive antigens can induce
a reaction. Also, as skin testing involves intradermal injection of
antigen into the person to be tested, repeated testing may cause a
sensitisation reaction, depending on the time interval between
testing [6,7]. The identification of M. tuberculosis specific antigens
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improved, next-generation, tuberculosis (TB) skin test reagents
with higher specificity, retained diagnostic sensitivity and low
sensitising properties. We have previously reported preliminary
results using rdESAT-6 as a skin test reagent in healthy adult
volunteers and in cured TB patients [8,9]. In the present study we
investigated increasing doses of a potential skin test reagent
composed of the species-specific rCFP10 and rdESAT6 antigens in
a first-in-man, phase I, clinical trial in healthy, adult volunteers.
Methods
Study design
The study was designed as an open, phase I clinical trial and
conducted at the Department of Infectious Diseases at Rigshos-
pitalet (a third level referral national hospital) in Copenhagen,
Denmark. The study included 42 non-black volunteers $18 years
of age from December 2008 to June 2009. Non-black volunteers
were selected to obtain the optimal conditions for an accurate
visual evaluation of the size of the skin test reactions (induration
and/or redness). The volunteers were mainly recruited by
advertising in newspapers and at bulletin boards at adjacent
educational institutions. All gave written informed consent prior to
inclusion and were healthy according to medical examination,
medical history and laboratory tests. The most important
exclusion criteria were: previous history of TB or known con-
tact to a person with active TB, positive IFN c response by
QuantiFERONH TB-Gold In-Tube test (QFT-IT) at inclusion,
volunteering in former trials assessing rdESAT-6, immunosup-
pressive treatment, congenital and/or acquired immune deficien-
cy, vaccination with live vaccines within the last 6 months, ongoing
viral and/or bacterial infection, severe skin disease and pregnancy.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Allocation in study groups. The trial was designed to
include 5 groups with 10 volunteers in each group. Group A and B
volunteers received two intradermal doses of 0.01 mg rdESAT-6
and rCFP-10 (w/w ratio 1:1), with time intervals of 6 weeks for
Group A and 12 weeks for Group B. Group C and D volunteers
received two intradermal doses of 0.1 mg of rdESAT-6 and rCFP-
10, with a time interval between the two doses of 6 weeks for
Group C and 12 weeks for Group D. Group E was scheduled to
receive only one dose of rdESAT-6 and rCFP-10 of 1.0 mg.
However, due to opacities observed visually in the vials containing
the highest concentration of the experimental skin test reagent, this
group was never recruited or initiated. A flow-chart describing the
experimental design is depicted in Figure 1. After being found
eligible for the trial at the inclusion visit the volunteers were
allocated to the first (not yet occupied) study group with an
acceptable time schedule in the order A, B, C and D.
Skin testing procedure. The rdESAT-6 and rCFP-10
reagent was injected by the Mantoux technique with a short-
bevelled sterile needle sized 0.45610 mm (26 Gauge) in the dorsal
aspect of the right (first injection) and left (second injection)
forearm, respectively. Observation of a small papule indicated
correct injection technique. During the first hour after the
injection, the volunteers were monitored closely for the
occurrence of immediate adverse reactions. For safety reasons
there was at least 1 hour between the injections of different
volunteers. Follow-up visits took place 72 hours after admini-
stration of the first dose and 72 hours and 28 days after
administration of the second dose. Digital photographs were
taken of all injection sites at the 72 hours visit. The diameters of
the skin indurations and/or redness of the injection sites were
measured transversally to the long axis of the forearm 72 hours
after both the first and second injection. ‘‘Redness’’ was defined as
visible red or pink discoloration of the skin around the injection
site and erythema $20 mm was regarded as a local adverse
reaction. ‘‘Induration’’ was measured by palpation from lateral to
central on all sites using a ball pen. Induration $6 mm was
regarded as a possible sensitisation reaction after the second
injection. A skin reaction after the first injection was regarded as a
sign of latent M. tuberculosis infection or an adverse reaction.
QFT-IT. In vitro IFN c responses were measured in blood
samples taken at the screening visit, prior to administration of the
second rdESAT-6 and rCFP-10 dose and at termination visit. An
IFN c response $0.35 IU/ml at screening was regarded as
possible M. tuberculosis infection. Responses occurring after the
second injection were regarded as possible sensitisation reactions.
The result of the second QFT-IT was not known when the second
Mantoux test with rdESAT-6 and rCFP-10 was administered. In
case of possible sensitisation reactions, specific IFN c responses
were measured by in vitro stimulation of Purified Blood
Mononucleated Cells (PBMC) from an extra blood sample with
a selected panel of antigens (see below) and an additional QFT-IT
test was performed.
Adverse events/reactions
All systemic and local adverse events occurring in the time
period between the first test administration and 28 days after the
second test administration were recorded. An adverse event was
defined as any untoward medical occurrence in a volunteer
exposed to the rdESAT-6 and rCFP-10 skin test regardless of
causal relationship with the product. Causality was assessed using
the terms: not related, possible, probable or certain. The intensity
was assessed using the terms: mild (easily tolerated), moderate
(interfere with daily activities) or severe (prevent normal activity).
Seriousness was assessed using standard terms. The volunteers
were asked to fill in diaries between the trial visits to keep track of
symptoms, temperature measurements and concomitant medica-
tion. All adverse events/reactions were coded using Medical
Dictionary for Regulatory Activities (MedDRA) preferred terms.
The investigational rdESAT-6 and rCFP-10 skin test
reagent
The investigational skin test reagent rdESAT-6 and rCFP-10
was manufactured at SSI, Denmark following Good Manufactur-
ing Practice (GMP) standards. The product is composed of
recombinant versions of the two M. tuberculosis derived antigens
ESAT-6 and CFP-10 cloned and expressed in Lactococcus lactis
[7,10]. rdESAT-6 is a dimeric version of ESAT-6 with 5 amino
acids extra at the N-terminal end of the protein and three amino
acids separating the two monomers. The rCFP-10 protein also has
an N-terminal extension of four amino acids. The two purified
proteins were mixed in a weight ratio of 1:1 in a vehicle of PBS
with 0.01% Polysorbate 20H and aliquots dispensed into vials for
storage at +2uCt o+8uC. ESAT-6 and CFP-10 form 1:1 complex
in nature [10].
In-house Interferon-Gamma Release Assay
Frozen human PBMCs were thawed and 2610
5 cells were
incubated in triplicate for five days at 37uC with 5% CO2 with
either culture medium alone, Staphylococcal Enterotoxin B at
1 ug/mL (Sigma cat. number S-4881, Sigma-Aldrich, DK) or
three different peptide mixtures at 2.5 ug/ml/peptide each. The
peptide mixtures were all spanning the entire protein of selected
Novel TB Skintest Reagent
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peptide, Germany) [11], ESAT-6 (13 peptides, 15-mer, 9 overlap;
JPT peptides, FRG) or CFP-10 (15 peptides, 15-mer, 9 overlap;
Genescript, USA). Subsequently IFN c was measured by ELISA in
the supernatants with a standard sandwich enzyme-linked
immunosorbent assay technique with a commercially available
pair of monoclonal antibodies (product # M700A and M701B,
Thermo Fisher Scientific Inc.) and used according to the
manufacturer’s instruction. Recombinant IFN c (product #
RIFNG50, Thermo Fisher Scientific Inc.) was used as a standard.
Figure 1. Flow diagram of study design. Participants were screened from 228 to 23 days before inclusion. The injections were given at day 0
and day 42 or on day 0 and day 84. Group A and B received 0.01 mg of the investigational skin test antigen. Group C and D received 0.1 mg. All
volunteers completed a final follow-up visit 28 days after the last injection.
doi:10.1371/journal.pone.0011277.g001
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Data safety monitoring board
A data safety monitoring board (DSMB) was established
consisting of three independent senior clinicians: two from other
Danish hospitals and one from a Dutch hospital. The principal
investigator was responsible for the safety of the volunteers.
However, DSMB members could be consulted for expert advice.
Sample size determination
The sample size was primarily based on practical and safety
issues and not statistical considerations. However, assuming the
risk of sensitisation defined as induration .6mm or IFN g
.0.35 IU/mL as measured in the QuantiFERON TB Gold
analysis after the second injection, increases with dose and for a
fixed dose of the experimental skintest reagent is higher if the two
doses are given with a 6 week interval than with a 12 week
interval. If none of the 40 participants in the groups show evidence
of sensitisation, then not only the 10 participants in that particular
group but also those receiving a higher dose and or shorter
injection interval can be taken into consideration in a conservative
calculation of a one-sided upper 95% CI for the risk of
sensitisation. With an effective sample size n, the conservative
one-sided upper 95% CI was calculated as [0, 12(120.95)
(1/n)]
resulting in a CI for sensitisation in the groups receiving the low
dose (0.01mg) of 0.00 to 0.07 with an effective sample size of 40
and for the high dose groups receiving 0.1mg the CI was 0.00 to
0.14 with an effective sample size of 20.
Ethical issues
The study was sponsored by SSI, Copenhagen, DK (Trial code
TESEC-01, EudraCT no.: 2008-001489-96) and conducted
according to ‘‘Note for guidance on good clinical practice’’,
CPMP/ICH/135/95, ICH topic E6 and CPMP/ICH/377/95 E
2A. The funder had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
The study was approved by the Danish Medical Ethics Committee
System (no: H-A-2008-105) and the Danish Data Protection
Agency (no: 2001-54-0877). The study was inspected and
approved with minor comments by the Danish Medicines Agency
before initiation (approval no: 2612-3851). The trial was filed in
the NIH clinical trials database: NCT00793702.
Results
42 volunteers (12 (29%) males were screened and all met the
inclusion criteria and were enrolled in the study. The mean age
was 36 years (SD 11,4 years), 40 were Danish and two volunteers
originated from another European country. Twenty (48%) had
been BCG vaccinated and 12 (29%) had previously had a TST.
One volunteer was excluded before the second injection was given
due to a positive pregnancy test. The volunteers were allocated by
order of appearance into four groups (Groups A to D) that differed
by the time intervals between the two injections and the dose level
of rdESAT-6 and rCFP-10 (Figure 1).
Group A
Group A included 7 women and 4 men, mean age 40 years (SD
11 years). Eight volunteers had a history of BCG-vaccination and
three reported a TST at some occasion, but could not recollect the
exact time. One person did not remember his BCG status. None of
the volunteers in Group A showed any positive skin reactions or
IFN c responses as measured by QFT-IT following the two
injections of 0.01 mg of rdESAT-6 and rCFP-10 with 6 weeks
interval.
Group B
Group B included 7 women and 3 men, mean age 33 years (SD
11 years).
Three volunteers had previously been BCG-vaccinated and two
had been skin tested before inclusion in the study, but were not
able to recall the exact time. None of the volunteers in group B
showed any positive reaction, neither skin reactions nor IFN c
responses by QFT-IT following two injections of 0.01 mgo f
rdESAT-6 and rCFP-10 with 12 weeks interval.
Group C
Group C included 7 women and 3 men, mean age 34 years (SD
12 years). Five volunteers reported previous BCG-vaccination and
three had been tuberculin skin tested at some unknown point of
time before inclusion in the study. One volunteer was unaware of
his vaccination and TST status. No positive skin reactions
occurred following the two intradermal injections of 0.1 mgo f
rdESAT-6 and rCFP-10 with 6 weeks interval. However, one
volunteer, a 23-year-old man, who had neither been BCG
vaccinated or skin tested previously and had a negative IFN c
response at screening of 0.02 IU/ml, showed a positive IFN c
response by QFT-IT of .10.0 IU/ml prior to administration of
the second injection, decreasing to 0.02 IU/ml 28 days later. At
this point in time an additional in-house IGRA was performed
showing no response to ESAT-6 or CFP-10 peptide stimulation
(Figure 2A). This finding confirmed the negative second QFT-IT
test result. He had no visible or palpable skin reaction. None of the
remaining volunteers in this group developed a positive IFN c
response.
Group D
Group D included 9 women and 2 men, mean age 37 years (SD
12 years). Four were previously BCG-vaccinated and four had a
history of a TST. Two persons were unaware of their status. One
55-year-old woman in this group withdrew from the trial just
before the second injection due to fear of side effects. A 34-year-
old woman developed a 20 mm induration and redness at the
injection site 72 hours after administration of the first dose of
rdESAT-6 and rCFP-10. She was not BCG-vaccinated, but had
received a TST 5 years previously. Furthermore, she had a
positive QFT-IT IFN c response of 1.57 IU/ml 96 hour after the
first injection. Noteworthy, this volunteer had the highest IFN c
response at the time of the screening visit at 0.24 IU/ml (cut off
point: 0.35 UI/ml). An additional in-house IGRA was performed
confirming the positive IFN cresponse to both ESAT-6 and CFP-
10 peptide stimulation as to peptides from TB10.4 protein: an M.
tuberculosis protein not present in the skin-test reagent (Figure 2B).
This participant was hereafter excluded from the study and did not
receive the second injection. None of the remaining 9 volunteers
showed any positive skin test or IFN c reactions.
Sensitisation results. 39 volunteers received two injections
and none of them experienced induration, erythema or a positive
QFT-IT INF c result 28 days after the second skin test (CI 0.1 mg/
0.1mL, short interval: 0.00–0.26; CI 0.1 mg/0.1mL, long interval:
0.00–0.19; total CI: 0.00–0.07).
Adverse reactions
No serious adverse events were reported. Twenty-nine of the 42
volunteers reported at least one adverse event: related or unrelated
to the skin test administration, but all of mild intensity. Twelve of
Novel TB Skintest Reagent
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relationship to the skin test administration could not be ruled
out. Eleven reactions were noted following the first injection and
five after the second injection (Table 1).
Discussion
In the process of developing a more specific and sensitive TB
skin test reagent, the recombinant dimeric version of ESAT-6 has
already been assessed in human phase I clinical trials involving
both healthy volunteers and TB patients [8,9]. Animal studies
have shown that combining ESAT-6 with the genetically related
CFP-10 protein increased sensitivity of the product without
hampering specificity [12]. Human in vitro studies have supported
that rCFP-10 can discriminate TB patients from BCG vaccinated,
healthy individuals [12].
This study describes the first in vivo experience with rCFP-10 as
a skin test reagent in humans. The study assessed two aspects: the
safety in a small scale, first-in-man study in healthy volunteers and
the potential risk of sensitisation induced by repeated doses of the
investigational skin test antigen. No serious adverse events were
observed during the study. Only mild and predictable events were
recorded. Positive QFT-IT IFN c reactions were induced in two
volunteers. In one case it was associated with a positive skin test
reaction after the first dose of antigen was injected. The
participant in question works as a nurse and was TST and
QFT-IT negative in 2004. She was never BCG vaccinated; she
had travelled on several occasions to TB high endemic countries
for recreational purposes but was not aware of exposure to TB
patients. Retrospectively it was noted that this person had a rather
high base-line QFT-IT IFN c production of 0.24 IU/ml. This is
below the QFT-IT test cut-off and is reported as a negative result,
but clearly higher than the rest of the study group (data not
shown). The most likely explanation is that this volunteer was in
fact latently infected with M. tuberculosis and the intradermal
injection of rdESAT-6 and rCFP-10 efficiently boosted her
memory T lymphocytes. The additional in vitro IGRA result
supports this hypothesis as she also recognised another M.
tuberculosis antigen besides ESAT-6 and CFP10. Sensitisation due
to a TST with PPD five year previously is unlikely [7,13]. Clinical
Figure 2. In vitro IFN c responses to selected antigens. PBMCs
from two volunteers were tested for in vitro IFN c responses to selected
M. tuberculosis antigens. A:volunteer from group C, TST negative, QFT-IT
positive after 1. injection, but negative after 2. injection and at day 28.
B: volunteer from group D, TST and QFT-IT positive after 1. injection and
hereafter excluded. PBMCs were stimulated for five days with culture
medium only (Nil), TB10.4 peptide mixture (TB10.4), ESAT-6 peptide
mixture (ESAT-6), CFP10 peptide mixture (CFP10) or Staphylococcal
Enterotoxin B (SEB) as a positive control. Subsequently, the superna-
tants were tested for IFN c content by ELISA. Bars indicate the mean
concentrations of IFN c in pg/mL of triplicate wells. Error bars indicate
the Standard Error of Mean. For each subject, the means of the peptide-
and SEB stimulated wells were compared to the mean of the
corresponding un-stimulated (Nil) wells by one-way analysis of variance
with Bonferoni post-test correction. ***: P,0.001, *:P,0.05, NS: Not
Significant (P.0.05).
doi:10.1371/journal.pone.0011277.g002
Table 1.
Adverse reactions Group A Group B Group C Group D All groups
N=11 N=10 N=10 N=11 N=42
nnnnn
Influenza like illness 2 1 7.1
Pruritus and pain 1 2.4
Skin hypopigmentation 1 2.4
Injection site pain 1 2.4
Headache 1 1 1 7.1
Application site bruising 2.4
Injection site discomfort and nausea 12 . 4
Body temperature changes
1 12 . 4
Abnormal standard blood safety tests
2 none none none none 0
N=number of subjects in group.
n=number of subjects in group experiencing adverse reaction.
%=percentage of subjects in trial experiencing adverse reaction.
1Recorded body temperature of 38.1uC.
2Blood samples at final visit for: Leukocytes (WBC) (eosinophils, basophils, neutrophils, lymphocytes,and monocytes), Platelets (Plts),Haemoglobin (Hb), C-reactive
protein (CRP), Glucose - random (GLU), Total bilirubin, Aspartate transferase (AST), Alanine transferase (ALT), Albumin (Alb), Creatinine, Potassium (K+), Sodium (Na+)a t
Visits 1 and 6. HIV, HBV and HCV only at Visit 1).
doi:10.1371/journal.pone.0011277.t001
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TB disease. Another theoretical consideration could be exposure
to and sensitisation by M. kansasii or M. marinum: two environ-
mental mycobaterial species known to possess ESAT-6 and CFP-
10 sensitising abilities [14]. However, the clinical history of this
volunteer did not support this as a possibility as she had never
suffered from pulmonary symptoms or had wound following
exposure to M. marinum infected water like e.g. fresh-water
aquariums.
One volunteer from Group C reacted positive in the QFT-IT
test 6 weeks after the first injection of a 0.1 mg dose. This subject
did not exhibit a positive skin reaction neither after the first nor the
second injection. He converted to being QFT-IT IFN c negative
in a follow-up test 4 weeks after the second injection and an
additional in vitro IGRA confirmed the follow-up negative QFT-
IT test result. The investigational skin test may have induced a
transitory immune reaction, which did not influence the skin test
result and appeared not to be boosted by the second injection. A
laboratory error in the IFN c detection is a trivial explanation that
cannot be ruled out. However, we have not been able to trace a
potential source of such error.
The risk of sensitisation after repeated rdESAT-6 skin testing in
30 healthy adults has previously been reported as low although
one person did develop a positive skin reaction after the second
injection of 0.1mg rdESAT-6 given 28 days after the second
injection [9]. In the present study the time interval between the
doses were increased and the antigen doses were lower. The
groups receiving the highest dose was given a total of 0.1 mg i.e.
0.05 mg of each of the two antigens which is only half the amount
given in the previous study. The frequency of adverse reactions
was lower in the present study compared to the previous study,
which may be ascribed to the reduced dose. However, larger
studies are required to give a true impression of the adverse
reaction profile. In conclusion, the combination of rdESAT-6 with
rCFP-10 in a novel skin test reagent appeared safe in this small-
scale first-in-man clinical trial. The product itself did not sensitise
non-immune healthy individuals. Larger clinical trials in relevant
patient groups or individuals exposed to TB patients are therefore
now being planned.
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